OncoMatch/Clinical Trials/NCT05475106
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms
Is NCT05475106 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Neoantigen Peptides for neoplasms.
Treatment: Neoantigen Peptides — The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
Lymphocyte ratio >20%; WBC >3.0×10^9/L; Normal blood coagulation function
Kidney function
BUN ≤1.5 × ULN; Creatinine ≤1.5 × ULN
Liver function
ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases); ALP ≤2.5 × ULN; TBIL < 1.5 × ULN
Cardiac function
Normal electrocardiogram (ECG)
Have adequate organ function, as measured by laboratory values: Lymphocyte ratio >20%; WBC >3.0×10^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if the patient has liver metastases, ALT and AST ≤5 × ULN; Alkaline phosphatase (ALP）≤2.5 × ULN; total serum bilirubin (TBIL) < 1.5 × ULN; Urea nitrogen (BUN）≤1.5 × ULN; Creatinine (Cr）1.5≤ULN; Normal blood coagulation function, urine routine, and electrocardiogram (ECG)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05475106 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify